Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension

Hypertension Research

Volumn 36, Issue 7, 2013, Pages 608-613

  Taguchi, Isao ^a   Toyoda, Shigeru ^a   Takano, Kazuhiko ^a   Arikawa, Takuo ^a   Kikuchi, Migaku ^a   Ogawa, Mikie ^a   Abe, Shichiro ^a   Node, Koichi ^b   Inoue, Teruo ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

angiotensin receptor blocker; inflammation; irbesartan; lipid metabolism; oxidative stress

Indexed keywords

ADIPONECTIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; VALSARTAN;

AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT; OXIDATIVE STRESS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BIPHENYL COMPOUNDS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PPAR GAMMA; RISK FACTORS; TETRAZOLES;

EID: 84881453397     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.3     Document Type: Article

References (35)

1. Siragy HM, Bedigian M. Mechanism of action of angiotensin-receptor blocking agent. Curr Hypertens Rep 1999; 1: 289-295.
2. Siragy HM. AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Am J Kidney Dis 2000; 36(Suppl 1): S4-S9.
3. Weir MR, Dzau VJ. The rennin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12: 205S-213S. (Pubitemid 30029273)
4. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113: 409-418. (Pubitemid 35230007)
5. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005; 18: 720-730. (Pubitemid 40692442)
6. Taguchi I, Inoue T, Kikuchi M, Toyoda S, Arikawa T, Abe S, Node K. Pleiotropic effects of angiotensin receptor blockers on dyslipidemia. Curr Vasc Pharmacol 2011; 9: 129-135.
7. Schpp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057. (Pubitemid 38620211)
8. Takai S, Jin D, Miyazaki M. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor g. J Pharmacol Sci 2011; 116: 309-315.
9. Kurtz T. New treatment strategies for patients with hypertension and insulin resistance. Am J Med 2006; 119: 24S-30S.
10. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity. Hypertension 2004; 43: 993-1002. (Pubitemid 38579904)
11. Chiarelli F, Di Marzio D, Santilli F, Mohn A, Blasetti A, Cipollone F, Mezzetti A, Verrotti A. Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. Diabetes Care 2005; 28: 1690-1697. (Pubitemid 40923079)
12. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-2141.
13. Carson RT, Vignali DAA. Simultaneous quantification of 15 cytokines using a multiplex flow cytometric assay. J Immnunol Methods 1999; 227: 41-52. (Pubitemid 29408703)
14. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10: 133-139. (Pubitemid 36133841)
15. Cearone MR, Belcalo G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L, Barsotti A, Terranova R, Nicolaides A. A simple test to monitor oxidative stress. Int Angiol 1999; 18: 127-130. (Pubitemid 29306588)
16. Cornelli U, Terranova R, Luca S, Cornelli S, Alberti A. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr 2001; 131: 3208-3211. (Pubitemid 33136136)
17. Cavalleri A, Colombo C, Venturelli E, Miceli R, Mariani L, Cornelli U, Pala V, Berrino F, Secreto G. Evaluation of reactive oxygen metabolites in frozen serum samples. Effect of storage and repeated thawing. Int J Biol Markers 2004; 19: 250-153.
18. Kehrer JP. The Haber-Weiss reaction and mechanisms of toxity. Toxicology 2000; 149: 43-55.
19. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
20. Lewis EJ, Hunsicker LG, Clarke WR, Beri T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz ICollaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
21. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska AI-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2457.
22. Yusuf S, Healy JS, Pogue J, Chrolavicus S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ, ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364: 928-938.
23. Lee C, Olson P, Evans RM. Minireview: lipid metabolism, metabolic disease, and peroxisome proliferator-activated receptors. Endocrinology 2003; 1446: 2201-2207. (Pubitemid 36629867)
24. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-139. (Pubitemid 29179280)
25. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81. (Pubitemid 36842239)
26. Agata J, Nagahara D, Kinoshita S, Takagawa Y, Moniwa N, Yoshida D, Ura N, Shimamoto K. Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J 2004; 68: 1194-1198. (Pubitemid 40018867)
27. Derosa G, Fogari E, D'Angelo A, Cicero AFG, Salvadeo SAT, Rogonesi PD, Ferrari I, Gravina A, Fassi R, Fogari R. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32: 261-268. (Pubitemid 46699517)
28. Inoue T, Node K. Telmisartan as a metabolic sartan for targeting vascular failure. Expert Opin Pharmacother 2008; 9: 1397-1406. (Pubitemid 351877522)
29. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for proxisome proliferator-activated receptorg (PPARg). J Biol Chem 1995; 270: 12953-12956.
30. Wakino S, Law RE, Hsuch WA. Vascular protective effects by activation of nuclear receptor PPAR-g. J Diabetes Complications 2002; 16: 46-49. (Pubitemid 34168500)
31. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003; 42: 664-668. (Pubitemid 37237306)
32. Campbell IW. The clinical significance of PPAR gamma agonism. Curr Mol Med 2005; 5: 349-363. (Pubitemid 40663140)
33. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21: 20-27. (Pubitemid 44921816)
34. Heinecke JW, Li W, Francis GA, Goldstein JA. Tyrosyl radical generated by myeloper-oxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest 1993; 91: 2866-2872. (Pubitemid 23182547)
35. Inoue T, Morooka T, Moroe K, Ikeda H, Node K. Effect of telmisartan on cholesterol levels in patients with hypertension-Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007; 39: 1-5.